News
INSM
96.47
+0.34%
0.33
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts
Benzinga · 1d ago
Insmed price target raised to $111 from $90 at JPMorgan
TipRanks · 1d ago
INSM Quantitative Stock Analysis
NASDAQ · 1d ago
Insmed Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
Insmed Price Target Raised to $111.00/Share From $90.00 by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on Insmed, Raises Price Target to $111
Benzinga · 1d ago
J.P. Morgan Sticks to Their Buy Rating for Insmed (INSM)
TipRanks · 2d ago
Weekly Report: what happened at INSM last week (0630-0704)?
Weekly Report · 3d ago
What Next For Liquidia After Launch?
Seeking Alpha · 06/30 14:40
Weekly Report: what happened at INSM last week (0623-0627)?
Weekly Report · 06/30 09:13
AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary
Seeking Alpha · 06/28 03:05
AMG GW&K Small Cap Core Fund Q1 2025 Commentary
Seeking Alpha · 06/26 02:40
Victory RS Small Cap Growth Fund Q1 2025 Commentary
Seeking Alpha · 06/25 15:16
Notable ETF Outflow Detected - XBI, INSM, ALNY, BPMC
NASDAQ · 06/25 14:52
Weekly Report: what happened at INSM last week (0616-0620)?
Weekly Report · 06/23 09:12
Tracking Baker Brothers Portfolio - Q1 2025 Update
Seeking Alpha · 06/18 01:14
Analysts Are Bullish on These Healthcare Stocks: Healthequity (HQY), Insmed (INSM)
TipRanks · 06/17 10:40
Notable ETF Outflow Detected - IWO, SFM, INSM, FTAI
NASDAQ · 06/16 14:49
Weekly Report: what happened at INSM last week (0609-0613)?
Weekly Report · 06/16 09:13
Insmed, Deutsche Bank, Booking, Uber, DoorDash: Trending by Analysts
TipRanks · 06/14 09:00
More
Webull provides a variety of real-time INSM stock news. You can receive the latest news about Insmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.